This refresh
Data-driven refresh July 2, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,230 tickers); 1,784 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.2
Health Information Services · price $21.86 · 1Y $24.37 · 5Y $35.68 · 10Y $52.93
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.3x B+ · PEG 0.59 A-
Why now. Doximity represents a high-quality compounder, trading at a compelling valuation given its profitability and growth trajectory. A PEG ratio of just 0.59 signals that its growth is significantly undervalued relative to its P/E of 22.3, while its robust free cash flow of $326m against a $4.0b market cap provides substantial financial flexibility. The core thesis rests on Doximity's ability to continue monetizing its specialized digital platform and workflow tools like Ask and Scribe, which are deeply embedded in the daily routines of medical professionals.
Moat. Doximity's durable competitive edge is built on a powerful network effect among medical professionals in the United States, who rely on its personalized newsfeed and HIPAA-compliant workflow tools. This deep integration into clinical workflows creates significant switching costs, reinforced by a stellar 20.6% Return on Equity, which reflects superior capital efficiency and pricing power derived from its category leadership in connecting and serving US physicians.
Risk. The primary bear case for Doximity centers on a potential deceleration in its revenue growth, currently at 13.1% FY YoY, which could struggle to justify a P/S of 6.2 if competition intensifies within the health information services sector. Furthermore, a high Beta of 1.29 suggests the stock is more sensitive to broader market downturns, potentially amplifying any growth slowdown. Confirmation of the bear case would be sustained revenue growth below 10% for two consecutive quarters, signaling market saturation or increased competitive pressure on its sponsored content business.
Horizon. 1-3 yr $24.37 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.68 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $52.93 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.5
Software - Application · price $219.72 · 1Y $279.87 · 5Y $409.76 · 10Y $607.85
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 12.6x A · PEG 0.56 A-
Why now. Adobe is a high-quality compounder trading at a significant discount, with its core Digital Media and Digital Experience segments continuing to drive robust cash flow. The company's P/E TTM of 12.6 and PEG ratio of 0.56 are remarkably low for a growth stock delivering 10.5% FY YoY revenue growth and a 28.7% profit margin. The market is overlooking the persistent demand for content creation and customer experience optimization, which ensures Adobe's strong free cash flow generation will continue to compound value for shareholders.
Moat. Adobe's formidable moat stems from the deep entrenchment of its Digital Media products among professionals like photographers, video editors, and graphic designers, creating high switching costs and a de facto industry standard. This ecosystem, combined with the integrated platform of its Digital Experience segment for brands and businesses, drives exceptional pricing power and sticky revenue. The company's impressive 62.8% ROE is a direct result of this category leadership and the mission-critical nature of its content creation and customer experience optimization tools.
Risk. The bear case centers on the potential for increased competition in both content creation and digital experience management, eroding Adobe's pricing power and growth trajectory. Despite its current low valuation multiples, the stock's beta of 1.4 indicates significant sensitivity to market downturns, reflecting investor uncertainty about its ability to maintain its growth rate. A sustained deceleration in its 10.5% FY YoY revenue growth, particularly within the Digital Media segment, would signal that new entrants or substitute solutions are successfully challenging Adobe's market dominance.
Horizon. 1-3 yr $279.87 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $409.76 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $607.85 if current growth sustains into durable earnings power.
3. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $90.44 · 1Y $104.01 · 5Y $152.28 · 10Y $225.89
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 14.2x A- · PEG 0.50 A
Why now. Stride’s integrated virtual‑school platform is the engine of its growth, delivering 17.9% YoY revenue expansion, a healthy 12.2% profit margin, and a rock‑bottom PEG of 0.5 that signals earnings will keep accelerating faster than the market expects. The combination of a low‑beta (0.08) stock and a modest PE of 14.2 gives investors a growth story at a valuation that still leaves ample upside. The thesis rests on the continued roll‑out of blended public‑school contracts that keep compounding revenue and cash flow.
Moat. Stride locks districts into a single, cloud‑based ecosystem that bundles curriculum, enrollment, progress‑tracking and support services, creating high switching costs for schools that have invested in its integrated workflow. Its 18.8% ROE stems from pricing power in the niche of virtual‑school infrastructure, where few competitors can match the breadth of proprietary and third‑party content bundled in one platform. The low beta (0.08) reflects the defensive nature of education spend, reinforcing the durability of cash‑flow generation.
Risk. The stock trades at roughly half its 52‑week high of $171.17, indicating the market has already punished it for a slowdown in district adoption and leaves little room for a rebound if funding for virtual programs stalls. With only two analysts covering LRN, the consensus target of $113.5 may be overly optimistic if revenue growth decelerates below the current 17.9% pace. A bear signal would be a breach of the $60.61 52‑week low coupled with a widening debt‑to‑equity ratio above 0.5, which would force the company to divert cash flow from growth to balance‑sheet repair.
Horizon. 1-3 yr $104.01 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $152.28 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $225.89 if current growth sustains into durable earnings power.
4. INTU — Intuit Inc. · score 89.1
Software - Application · price $275.35 · 1Y $486.61 · 5Y $712.45 · 10Y $1,057
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 16.8x A- · PEG 0.68 A-
Why now. Intuit’s QuickBooks ecosystem, now bolstered by Mailchimp’s marketing automation, creates a sticky, cross‑sell platform for the $75.3B SMB market, driving relentless revenue expansion. The business is delivering 15.6% YoY revenue growth, 21.9% profit margin and 22.2% ROE, all while generating $7.8B of free cash flow—a rare blend of growth and cash generation that fuels compounding for the next decade.
Moat. The moat lives in the integrated QuickBooks suite—accounting, payroll, payments, financing and now Mailchimp CRM—which locks SMBs into a single data hub, creating high switching costs and pricing power that underpins the 22.2% ROE. This end‑to‑end workflow cannot be replicated quickly by rivals without massive product and integration investments.
Risk. A bear sees the growth engine stalling: the 15.6% revenue acceleration is already modest for a SaaS leader, and any slowdown would pressure the PE of 16.8x and compress margins below the current 21.9%. Competitive pressure from other cloud accounting providers could erode the cross‑sell advantage, and a breach of the 52‑week low of $252.84 would signal a market‑wide re‑rating. Confirmation would be a quarterly revenue growth dip below 10% and a widening of the analyst target range.
Horizon. 1-3 yr $486.61 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $712.45 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,057 if current growth sustains into durable earnings power.
5. PCTY — Paylocity Holding Corporation · score 88.5
Software - Application · price $115.10 · 1Y $152.42 · 5Y $223.16 · 10Y $331.04
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 24.6x B+ · PEG 0.88 B+
Why now. Paylocity's integrated cloud-based human capital management and payroll software solutions are driving consistent growth, evidenced by a robust 14.8% FY YoY revenue growth and a highly attractive 0.88 PEG ratio. The company's ability to generate significant $487m in TTM free cash flow at a 16.1% profit margin underscores its operational efficiency and capacity to reinvest in its comprehensive suite of payroll, HR, time & labor, and talent solutions, ensuring continued compounding in a sticky software market. The crux is the persistent demand for unified, efficient workforce management platforms.
Moat. Paylocity's durable edge stems from the high switching costs associated with its deeply integrated cloud-based human capital management and payroll software. Businesses are reluctant to disrupt core operations like payroll and HR, creating stickiness for Paylocity's comprehensive offerings, including global payroll and talent solutions like recruiting and performance management. This operational embeddedness, combined with a 21.9% ROE, reflects pricing power derived from being a critical, indispensable platform for workforce management, making it difficult for competitors to dislodge.
Risk. The primary bear case for Paylocity centers on the competitive intensity within the cloud-based HCM and payroll software market, where larger players could pressure pricing or outspend on R&D, potentially decelerating Paylocity's growth. While the 24.6 P/E (TTM) is reasonable for a growth stock, a sustained slowdown in its 14.8% revenue growth could lead to multiple compression, especially given the stock's significant drop from its $197.78 52-week high. A concrete signal confirming the bear case would be a material deceleration in new client acquisition or a contraction in profit margins as a result of increased competitive discounting.
Horizon. 1-3 yr $152.42 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $223.16 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $331.04 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 87.4
Drug Manufacturers - Specialty & Generic · price $174.26 · 1Y $195.99 · 5Y $247.43 · 10Y $317.32
FCF $831m C+ · Rev +21.4% A- · D/E 0.14 B+ · P/E 26.9x B · PEG 0.48 A
Why now. Drug Manufacturers - Specialty & Generic · market cap $17.5b. Trading near 52-week high of $174.38 — momentum setup, limited technical margin of safety. Revenue growing +21%, comfortably above the S&P median. PEG 0.48 — paying under fair value for the growth rate. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $195.99 (implying +12% upside).
Moat. Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $195.99 (analyst consensus (n=28)) — multiple re-rating thesis requires a catalyst. 5 yr $247.43 at ~7% CAGR — dividend + buyback compounding. 10 yr $317.32 if the moat survives secular pressure.
7. ADMA — ADMA Biologics, Inc. · score 87.2
Biotechnology · price $8.95 · 1Y $17.60 · 5Y $22.22 · 10Y $28.50
FCF $108m C · Rev +19.6% B+ · D/E 1.11 C · P/E 13.2x A- · PEG 0.67 A-
Why now. Biotechnology · market cap $2.1b. Down 56% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.67 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $17.60 (implying +97% upside).
Moat. Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk. Down 56% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — multiple re-rating thesis requires a catalyst. 5 yr $22.22 at ~20% CAGR — dividend + buyback compounding. 10 yr $28.50 if the moat survives secular pressure.
8. NVDA — NVIDIA Corporation · score 86.4
Semiconductors · price $194.83 · 1Y $301.62 · 5Y $380.79 · 10Y $488.35
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 29.9x B · PEG 0.61 A-
Why now. Semiconductors · market cap $4.7T. 18% off the 52-week high of $236.54. Revenue growing +65% — in hypergrowth territory. PEG 0.61 — paying under fair value for the growth rate. 58 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $301.62 (implying +55% upside).
Moat. Net margin 63% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 82% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $4.7T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Beta 2.20 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. P/S 18.6x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Semiconductor cyclicality — inventory corrections compress margins faster than analysts model. Monitor channel inventory and book-to-bill ratios as leading indicators.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — multiple re-rating thesis requires a catalyst. 5 yr $380.79 at ~14% CAGR — dividend + buyback compounding. 10 yr $488.35 if the moat survives secular pressure.
9. EXLS — ExlService Holdings, Inc. · score 86.1
Information Technology Services · price $27.02 · 1Y $41.75 · 5Y $52.71 · 10Y $67.60
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 17.2x A- · PEG 0.83 B+
Why now. Information Technology Services · market cap $4.1b. Down 43% from 52-week high of $47.11 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.83 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $41.75 (implying +55% upside).
Moat. ROE 32% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 118% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 43% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — multiple re-rating thesis requires a catalyst. 5 yr $52.71 at ~14% CAGR — dividend + buyback compounding. 10 yr $67.60 if the moat survives secular pressure.
10. HRMY — Harmony Biosciences Holdings, Inc. · score 85
Biotechnology · price $37.26 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +21.5% A- · D/E 0.18 B+ · P/E 15.0x A- · PEG 0.70 A-
Why now. Harmony’s WAKIX (pitolisant) is the only FDA‑approved narcolepsy therapy with a novel histamine‑based mechanism, giving it pricing power that fuels a profit margin of 16.2% and a healthy PE of 15 on a growth trajectory of 21.5% revenue growth YoY. The drug’s market‑leading status drives free cash flow of $342 m against a $2.2 b market cap, delivering a >15% FCF yield that can be reinvested into its Phase 3 PWS trial and other pipeline assets. The thesis hinges on the compounding effect of expanding rare‑neurology indications while the balance sheet remains low‑leverage.
Moat. WAKIX’s novel mechanism and FDA approval create a high switching cost for narcolepsy patients and neurologists, effectively locking in a captive rare‑disease market where competitors lack a comparable drug. This pricing power translates into a solid ROE of 16%, reflecting the company’s ability to earn above‑average returns on capital without heavy debt (debt‑to‑equity 0.18). The pipeline’s Phase 2/3 pitolisant extensions (PWS, Myotonic Dystrophy) further cement the moat by leveraging the same molecule across multiple orphan indications.
Risk. The business is heavily dependent on WAKIX; any regulatory setback or failure in the Phase 3 Prader‑Willi trial would strip away the primary revenue engine and stall cash‑flow generation. While the stock trades at a modest PE of 15, the forward growth premium is baked into the PEG of 0.7, leaving limited upside if the pipeline stalls. A decisive bear signal would be a missed primary endpoint in the PWS trial, triggering a price slide back toward the 52‑week low of $25.52.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
11. IT — Gartner, Inc. · score 84.6
Information Technology Services · price $136.32 · 1Y $165.00 · 5Y $208.31 · 10Y $267.15
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 13.5x A- · PEG 0.52 A-
Why now. Information Technology Services · market cap $9.1b. Down 66% from 52-week high of $403.96 — deep drawdown territory. PEG 0.52 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $165.00 (implying +21% upside).
Moat. FCF converts 170% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 66% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — multiple re-rating thesis requires a catalyst. 5 yr $208.31 at ~9% CAGR — dividend + buyback compounding. 10 yr $267.15 if the moat survives secular pressure.
12. EPAM — EPAM Systems, Inc. · score 84
Information Technology Services · price $88.27 · 1Y $144.06 · 5Y $181.87 · 10Y $233.24
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 12.7x A · PEG 0.41 A
Why now. Information Technology Services · market cap $4.6b. Down 60% from 52-week high of $222.53 — deep drawdown territory. Revenue growing +15%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $144.06 (implying +63% upside).
Moat. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 60% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $144.06 (analyst consensus (n=18)) — multiple re-rating thesis requires a catalyst. 5 yr $181.87 at ~16% CAGR — dividend + buyback compounding. 10 yr $233.24 if the moat survives secular pressure.
13. DXCM — DexCom, Inc. · score 83.7
Medical Devices · price $71.25 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +15.6% B+ · D/E 0.47 B · P/E 30.6x B · PEG 1.28 B
Why now. Medical Devices · market cap $27.5b. Down 21% from 52-week high of $89.98 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $85.24 (implying +20% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 31% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 154% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Beta 1.44 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
14. CARG — CarGurus, Inc. · score 82.9
Auto & Truck Dealerships · price $36.24 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 19.1x B · PEG 1.07 B+
Why now. CarGurus’ Digital Deal platform converts its huge online shopper audience into a sticky, high‑margin revenue stream, fueling 13.7% YoY revenue growth, 15.9% profit margin, and an eye‑popping 62.9% ROE – a compounding engine that will keep cash flowing as more dealers subscribe to its marketplace. The thesis rests on the network effect of shoppers and dealers that makes each new user amplify the value of the whole ecosystem, ensuring growth persists.
Moat. The integrated online marketplace and dealer‑subscription model lock dealers into a data‑rich, lead‑generation hub that competitors can’t replicate quickly, creating a switching cost for both dealers and shoppers. This lock‑in drives pricing power, evident in the 62.9% ROE, because CarGurus can command premium fees while delivering measurable sales pipelines. The scale of its shopper base further entrenches the moat, as every additional dealer amplifies the platform’s reach.
Risk. A 19.1 P/E for a growth name leaves little margin for error, and a debt‑to‑equity of 0.79 adds financial leverage that could bite if revenue growth stalls. The beta of 1.21 makes the stock vulnerable to market swings, while intensifying competition in the online auto‑retail space could compress the 15.9% margin. A bear signal would be a slowdown of revenue growth to single‑digit percentages or margin erosion below 12% for two quarters in a row.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
15. RMD — ResMed Inc. · score 82.6
Medical Instruments & Supplies · price $209.63 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
FCF $1.8b C+ · Rev +9.8% B · D/E 0.13 B+ · P/E 20.2x B+ · PEG 1.15 B+
Why now. Medical Instruments & Supplies · market cap $30.4b. Down 29% from 52-week high of $293.81 — deep drawdown territory. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $260.60 (implying +24% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
16. VEEV — Veeva Systems Inc. · score 82.5
Health Information Services · price $192.74 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 34.2x C+ · PEG 0.80 A-
Why now. Health Information Services · market cap $31.3b. Down 38% from 52-week high of $310.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.80 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $244.59 (implying +27% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 38% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 34x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
17. META — Meta Platforms, Inc. · score 82.2
Internet Content & Information · price $582.90 · 1Y $828.13 · 5Y $1,046 · 10Y $1,341
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 21.2x B · PEG 0.81 B+
Why now. Internet Content & Information · market cap $1.5T. Down 27% from 52-week high of $796.25 — deep drawdown territory. Revenue growing +22%, comfortably above the S&P median. PEG 0.81 — paying under fair value for the growth rate. 58 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $828.13 (implying +42% upside).
Moat. Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.5T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $828.13 (analyst consensus (n=58)) — multiple re-rating thesis requires a catalyst. 5 yr $1,046 at ~12% CAGR — dividend + buyback compounding. 10 yr $1,341 if the moat survives secular pressure.
18. CVSA — Covista Inc. · score 81.4
Education & Training Services · price $129.88 · 1Y $156.25 · 5Y $197.26 · 10Y $252.98
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 18.9x B · PEG 0.88 B+
Why now. Education & Training Services · market cap $4.4b. 17% off the 52-week high of $156.26. Revenue growing +13%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $156.25 (implying +20% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 144% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — multiple re-rating thesis requires a catalyst. 5 yr $197.26 at ~9% CAGR — dividend + buyback compounding. 10 yr $252.98 if the moat survives secular pressure.
19. MELI — MercadoLibre, Inc. · score 80.4
Internet Retail · price $1763.36 · 1Y $2,209 · 5Y $3,234 · 10Y $4,797
FCF $11.8b A- · Rev +34.3% A · D/E 1.70 C+ · P/E 46.6x C · PEG 1.05 B+
Why now. Internet Retail · market cap $89.4b. Down 31% from 52-week high of $2548.50 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $2,209 (implying +25% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $89.4b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 47x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. E-commerce competition — Amazon, Walmart, Shein, and Temu have each forced the rest of the category to compete on price, fulfillment speed, or assortment; sustaining margins requires one of those being structurally defended.
Horizon. 1-3 yr $2,209 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,234 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $4,797 if current growth sustains into durable earnings power.
20. QCOM — QUALCOMM Incorporated · score 80
Semiconductors · price $176.25 · 1Y $215.42 · 5Y $271.96 · 10Y $348.78
FCF $12.5b A- · Rev +13.7% B+ · D/E 0.56 C+ · P/E 19.0x A- · PEG 0.58 A-
Why now. Semiconductors · market cap $185.8b. Down 32% from 52-week high of $259.92 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.58 — paying under fair value for the growth rate. 31 sell-side analysts rate this a Hold with a mean 1-yr target of $215.42 (implying +22% upside).
Moat. Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 36% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 126% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.60 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Semiconductor cyclicality — inventory corrections compress margins faster than analysts model. Monitor channel inventory and book-to-bill ratios as leading indicators.
Horizon. 1-3 yr $215.42 (analyst consensus (n=31)) — multiple re-rating thesis requires a catalyst. 5 yr $271.96 at ~9% CAGR — dividend + buyback compounding. 10 yr $348.78 if the moat survives secular pressure.
21. PODD — Insulet Corporation · score 79.4
Medical Devices · price $164.48 · 1Y $240.25 · 5Y $351.75 · 10Y $521.80
FCF $416m C · Rev +30.7% A · D/E 0.78 C+ · P/E 38.4x C+ · PEG 1.41 B
Why now. Medical Devices · market cap $11.4b. Down 54% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 24 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $240.25 (implying +46% upside).
Moat. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 137% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 54% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 38x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $240.25 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $351.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $521.80 if current growth sustains into durable earnings power.
22. FIVE — Five Below, Inc. · score 79.1
Specialty Retail · price $182.43 · 1Y $260.81 · 5Y $329.27 · 10Y $422.28
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 23.0x B · PEG 0.98 B+
Why now. Specialty Retail · market cap $10.1b. Down 28% from 52-week high of $251.63 — deep drawdown territory. Revenue growing +23%, comfortably above the S&P median. PEG 0.98 — paying under fair value for the growth rate. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $260.81 (implying +43% upside).
Moat. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $260.81 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $329.27 at ~13% CAGR — dividend + buyback compounding. 10 yr $422.28 if the moat survives secular pressure.
23. DECK — Deckers Outdoor Corporation · score 79
Footwear & Accessories · price $104.69 · 1Y $126.86 · 5Y $160.15 · 10Y $205.39
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.9x A- · PEG 1.25 B
Why now. Footwear & Accessories · market cap $14.5b. 17% off the 52-week high of $126.50. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $126.86 (implying +21% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $160.15 at ~9% CAGR — dividend + buyback compounding. 10 yr $205.39 if the moat survives secular pressure.
24. NFLX — Netflix, Inc. · score 78.8
Entertainment · price $77.65 · 1Y $114.15 · 5Y $167.12 · 10Y $247.91
FCF $11.9b A- · Rev +15.9% B+ · D/E 0.54 B · P/E 25.0x B · PEG 1.40 B
Why now. Entertainment · market cap $327.0b. Down 40% from 52-week high of $130.23 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 44 sell-side analysts rate this a Buy with a mean 1-yr target of $114.15 (implying +47% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $327.0b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 40% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.49 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $114.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $167.12 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $247.91 if current growth sustains into durable earnings power.
25. FISV — Fiserv, Inc. · score 75.7
Sector n/a · price $52.33 · 1Y $70.00 · 5Y $88.37 · 10Y $113.34
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.9x A- · PEG 2.46 C
Why now. Sector n/a · market cap $27.9b. Down 70% from 52-week high of $175.92 — deep drawdown territory. 26 sell-side analysts rate this a Hold with a mean 1-yr target of $70.00 (implying +34% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 70% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $88.37 at ~11% CAGR — dividend + buyback compounding. 10 yr $113.34 if the moat survives secular pressure.
26. YUMC — Yum China Holdings, Inc. · score 75.5
Restaurants · price $41.70 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +4.4% C+ · D/E 0.38 A- · P/E 16.0x B+ · PEG 1.02 B+
Why now. Restaurants · market cap $14.4b. Down 29% from 52-week high of $58.39 — deep drawdown territory. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $61.34 (implying +47% upside).
Moat. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
27. ULTA — Ulta Beauty, Inc. · score 75
Specialty Retail · price $461.33 · 1Y $627.25 · 5Y $918.36 · 10Y $1,362
FCF $1.1b C+ · Rev +9.7% B · D/E 0.89 B · P/E 17.3x B+ · PEG 1.57 C+
Why now. Specialty Retail · market cap $19.8b. Down 35% from 52-week high of $714.97 — deep drawdown territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $627.25 (implying +36% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $627.25 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $918.36 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,362 if current growth sustains into durable earnings power.
28. SE — Sea Limited · score 74
Internet Retail · price $103.30 · 1Y $140.26 · 5Y $205.35 · 10Y $304.62
FCF $4.5b B · Rev +36.4% A · D/E 0.28 A- · P/E 40.7x C · PEG 1.38 B
Why now. Internet Retail · market cap $63.3b. Down 48% from 52-week high of $199.30 — deep drawdown territory. Revenue growing +36% — in hypergrowth territory. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $140.26 (implying +36% upside).
Moat. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $63.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 48% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.57 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $140.26 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $205.35 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $304.62 if current growth sustains into durable earnings power.
29. EME — EMCOR Group, Inc. · score 73.9
Engineering & Construction · price $774.66 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +16.6% B+ · D/E 0.13 A- · P/E 26.0x B · PEG 0.44 A
Why now. Engineering & Construction · market cap $34.5b. 19% off the 52-week high of $951.96. Revenue growing +17%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 7 sell-side analysts publish a mean 1-yr target of $1,000 (implying +29% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
30. VST — Vistra Corp. · score 73.8
Utilities - Independent Power Producers · price $151.05 · 1Y $222.89 · 5Y $281.39 · 10Y $360.88
FCF $1.8b C+ · Rev +19.1% B+ · D/E 3.55 D · P/E 25.3x C · PEG 0.47 A
Why now. Utilities - Independent Power Producers · market cap $50.9b. Down 31% from 52-week high of $219.82 — deep drawdown territory. Revenue growing +19%, comfortably above the S&P median. PEG 0.47 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $222.89 (implying +48% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 40% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $50.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. D/E 3.55 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $222.89 (analyst consensus (n=18)) — multiple re-rating thesis requires a catalyst. 5 yr $281.39 at ~13% CAGR — dividend + buyback compounding. 10 yr $360.88 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.